- Home
- IHT vs CANF Comparison
IHT vs CANF Comparison
Compare IHT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IHT | CANF |
|---|---|---|
| Founded | 1971 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 4.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IHT | CANF |
|---|---|---|
| Price | $1.35 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.25 |
| AVG Volume (30 Days) | 31.1K | ★ 19.8M |
| Earning Date | 12-15-2025 | 02-03-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,443,699.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.25 | $0.26 |
| 52 Week High | $4.24 | $2.33 |
Technical Indicators
Market Signals| Indicator | IHT | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 33.77 |
| Support Level | $1.25 | $0.26 |
| Resistance Level | $1.52 | $0.30 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 33.33 | 8.75 |
Price Performance
Historical ComparisonAbout IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).